Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Maffezzini

European urology

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
European Urology|November 23, 2006
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancerMassimo Maffezzini, Alberto Bossi, Laurence Collette
European Urology|October 10, 2006
Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladderMassimo Maffezzini, Fabio Campodonico, Giorgio Canepa, et al.
European Urology|September 15, 2004
Bladder cell culture on small intestinal submucosa as bioscaffold: experimental study on engineered urothelial graftsFabio Campodonico, Roberto Benelli, Alberto Michelazzi, et al.
European Urology|January 25, 2016
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder CancerTom J H Arends, Ofer Nativ, Massimo Maffezzini, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
European Urology|November 23, 2006
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancerMassimo Maffezzini, Alberto Bossi, Laurence Collette
European Urology|October 10, 2006
Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladderMassimo Maffezzini, Fabio Campodonico, Giorgio Canepa, et al.
European Urology|September 15, 2004
Bladder cell culture on small intestinal submucosa as bioscaffold: experimental study on engineered urothelial graftsFabio Campodonico, Roberto Benelli, Alberto Michelazzi, et al.
European Urology|January 25, 2016
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder CancerTom J H Arends, Ofer Nativ, Massimo Maffezzini, et al.
Pageof 1